Form 8-K · Current report

Edwards Lifesciences 8-K, filed Aug 28, 2026

Filed
CIK
0001099800
Accession no.
0001099800-26-000048
AI-generated summary

Summary

Edwards Lifesciences has received notice from Donald E. Bobo, Jr., Corporate Vice President, Strategy and Corporate Development, that he will retire from the company by mid-year 2027. The company will begin a successor selection process, with a transition of duties expected during 2027, and Bobo is expected to remain a consultant through the end of that year.

Key points

  • Donald E. Bobo, Jr. is Corporate Vice President, Strategy and Corporate Development at Edwards Lifesciences.
  • A successor selection process will begin promptly, with a transition of duties expected during 2027.
  • Bobo is expected to remain as a consultant with the Company through the end of 2027.

Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.

Items reported

  • 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

From the filing

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The Board of Directors of Edwards Lifesciences Corporation, a Delaware corporation (“Edwards” or the “Company”), has received notice from Donald E. Bobo, Jr., Corporate Vice President, Strategy and Corporate Development, of his decision to retire from the Company by mid-year 2027. A selection process will begin promptly to identify a successor, which is expected to result in a transition of duties during 2027. Mr. Bobo is also expected to remain as a consultant with the Company through the end of 2027. 2

An excerpt of the text as filed with the SEC, cut for length.

Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.

Follow Edwards Lifesciences in Readster

Add Edwards Lifesciences to your watchlist and its SEC filings reach your brief alongside the news about it, every line cited to its source. Readster also follows topics, people, newsletters and podcasts.

No credit card. When the trial ends, you move to Readster Free unless you subscribe.